DNA Facility

项目总结（见说明）： DNA测序设施（DSF）为研究人员提供高质量的DNA测序。在2009年，该设施被43个同行评审，资助研究人员在四个中心的五个研究项目。百分之九十八点五（98.5%）的使用是为了支持同行评审，资助的研究人员。哈代（免疫细胞发育和宿主防御（ICDHD）计划）于1993年担任该设施的领导。2004年，所有自动测序仪都被替换为 单个ABI 3100毛细管仪器，提供更可靠的高通量测序。ABI 3100于2007年升级为3130型。DSF为Fox Chase癌症中心（FCCC）的研究人员提供了他们DNA样本的计算机可读序列，并以及时和具有成本效益的方式提供。自动序列分析被研究者用来验证DNA结构，识别突变，并确定 新克隆基因的结构。该设施的使用量继续保持在高水平，在过去五年中平均每年16 000个序列。基金咨询委员会（FAC）和基金母公司监督委员会（FPOC）的建议确保了基金的公平准入和业务监督。

PROJECT SUMMARY (See instructions): The DNA Sequencing Facility (DSF) provides investigators with high quality DNA sequencing. In calendar year 2009, the Facility was used by 43 peer-reviewed, funded investigators across four of the Center's five Research Programs. Ninety-eight and one-half percent (98.5%) of use is in support of peer-reviewed, funded investigators. Hardy (Immune Cell Development and Host Defense (ICDHD) Program) assumed direction of the Facility in 1993. In 2004 all automated sequencers were replaced by a single ABI 3100 capillary instrument, providing more reliable high-throughput sequencing. The ABI 3100 was upgraded to a model 3130 in 2007. The DSF provides Fox Chase Cancer Center (FCCC) investigators with computer-readable sequences of their DNA samples in a timely and cost effective manner. Automated sequence analysis is used by investigators to verify DNA constructs, to identify mutations, and to determine the structure of newly cloned genes. The volume of usage of the Facility has continued at a high level averaging 16,000 sequences per year over the last five years. Equitable access and operational oversight of the Facility are assured by recommendations from a Facility Advisory Committee (FAC) and the Facility Parent Oversight Committee (FPOC).